
Congress reached an agreement on a $1.3 trillion spending bill that includes a provision allowing gun violence research, but does not include 2 drug pricing measures or a provision to stabilize the Affordable Care Act markets; and FDA has released 2 draft guidances on postmarketing safety reporting requirements.